Wilhelm A J W Vos, Nadira Vadaq, Vasiliki Matzaraki, Twan Otten, Albert L Groenendijk, Marc J T Blaauw, Louise E van Eekeren, Kees Brinkman, Quirijn de Mast, Niels P Riksen, Anton F H Stalenhoef, Jan van Lunzen, Andre J A M van der Ven, Willem L Blok, Janneke E Stalenhoef
In people living with HIV (PLHIV), integrase strand transfer inhibitors (INSTIs) are part of the first-line combination antiretroviral therapy (cART), while non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens are alternatives. Distinct cART regimens may variably influence the risk for non-AIDS comorbidities. We aimed to compare the metabolome and lipidome of INSTI and NNRTI-based regimens. The 2000HIV study includes asymptomatic PLHIV (n = 1646) on long-term cART, separated into a discovery cohort with 730 INSTI and 617 NNRTI users, and a validation cohort encompassing 209 INSTI and 90 NNRTI users...
April 10, 2024: Viruses